BBA
VIR icon

Baker Bros. Advisors’s Vir Biotechnology VIR Stock Holding History

Baker Bros. Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-542,539
Closed -$3.27M – 92
2025
Q4 		$3.27M Hold
542,539
– – 0.02% 78
2025
Q3 		$3.1M Hold
542,539
– – 0.02% 78
2025
Q2 		$2.73M Hold
542,539
– – 0.03% 73
2025
Q1 		$3.52M Sell
542,539
-542,000
-50% -$4.82M 0.04% 66
2024
Q4 		$7.96M Buy
+1,084,539
New +$8.55M 0.09% 58

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Baker Bros. Advisors's VIR Position: Q1 2026 in Review

Baker Bros. Advisors sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 542,539 shares — an estimated $3.27M sold.

Baker Bros. Advisors first reported a position in VIR in Q4 2024 and held it in 5 quarters. The position peaked at $7.96M in Q4 2024. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Baker Bros. Advisors reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Baker Bros. Advisors sold 542,539 Vir Biotechnology shares in Q1 2026, an estimated $3.27M.
  • Baker Bros. Advisors first reported a position in Vir Biotechnology in Q4 2024 and held it in 5 quarters.
  • Baker Bros. Advisors's Vir Biotechnology position peaked at $7.96M in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.